Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Prometheus Biosciences, Inc. RXDX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$138.57
-30.7%

Prometheus Biosciences, Inc. (RXDX) is a Biotechnology company in the Healthcare sector, currently trading at $199.92. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is RXDX = $139 (-30.7% upside).

Financials: revenue is $7M, +94%/yr average growth. Net income is $142M (loss), growing at -71.8%/yr. Net profit margin is -2081.8% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $30M against $676M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 31.04 (strong liquidity). Debt-to-assets is 4%. Total assets: $741M.

Analyst outlook: 4 / 11 analysts rate RXDX as buy (36%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).

$138.57
▼ 30.69% Downside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Prometheus Biosciences, Inc., the average price target is $138.57, with a high forecast of $200.00, and a low forecast of $67.00.
Highest Price Target
$200.00
Average Price Target
$138.57
Lowest Price Target
$67.00

RXDX SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RXDX

✗
VALUE Fail
10/100
RXDX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $139, implying -30.5% from the current price $200. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
RXDX: +94%/yr revenue is, -71.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RXDX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 31.04 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
RXDX: Gross margin is 100% (+0 pp trend), $10B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 4 / 11 analysts rate RXDX as buy (36%). Analyst consensus target is $139 (-30.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
RXDX: Net profit margin is -2081.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range23.27-199.96
Volume1.79M
Avg Volume (30D)1.22M
Market Cap$9.56B
Beta (1Y)-0.49
Share Statistics
EPS (TTM)-3.49
Shares Outstanding$40.62M
IPO Date2021-03-12
Employees97
CEOMark C. McKenna
Financial Highlights & Ratios
Revenue (TTM)$6.81M
Gross Profit$6.81M
EBITDA$-145.78M
Net Income$-141.75M
Operating Income$-145.78M
Total Cash$695.75M
Total Debt$29.54M
Net Debt$-262.89M
Total Assets$740.77M
Price / Earnings (P/E)-57.3
Price / Sales (P/S)1403.81
Analyst Forecast
1Y Price Target$142.00
Target High$200.00
Target Low$67.00
Upside-29.0%
Rating ConsensusHold
Analysts Covering11
Buy 36% Hold 64% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS74349U1088

Price Chart

Track all markets on TradingView
RXDX
Prometheus Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
23.27 52WK RANGE 199.96

People Also View

ROIV
ROIV
Roivant Sciences Ltd.
$29.12
+0.59%
 KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message